Liquid Biopsy Market Size, Industry Analysis Report, Regional Outlook, Application Potential, Price Trends, Competitive Market Share & Forecast, 2021 – 2027
Report ID: GMI3775
Liquid Biopsy Market size is projected to experience significant growth from 2019 to 2025.
Growing prevalence of cancer across the globe will stimulate the global liquid biopsy market growth over the forthcoming years. According to the World Health Organization, cancer is the second leading cause of death worldwide, accounting over 9.6 million deaths in 2018. Rising alcohol and tobacco consumption have led to rise in global cancer burden. As per World Cancer Report, prevalence of cancer is estimated to increase by approximately 50%, reaching over 15 million new cancer cases by 2020. Thus, increasing disease incidence coupled with minimally invasive technology for cancer diagnosis will augment the market growth.
Increasing preference for minimally invasive procedures will expand liquid biopsy market size in the upcoming period. Liquid biopsy is a safe, pain-free and effective method to detect cancer and other abnormalities. The technology makes use of specimens such as saliva, cerebrospinal fluid, urine or other tissue fluids for detection of biomarkers, thus escalating the customer preference. Furthermore, growing advancements and commercialization of liquid biopsy assays by leading players will boost the liquid biopsy industry growth over the foreseeable future.
However, ambiguous regulatory scenario and presence of alternatives for liquid biopsy including solid biopsy and digital imaging may impede the industry growth.
Liquid biopsy services market will account for significant market size during the forecast timeframe. Rising demand for laboratory services due to better cost-effectivity and no requirement for specialized workforce will impel the segmental growth. Furthermore, high costs associated with the liquid biopsy procedures, will spur the demand for liquid biopsy services in the coming years.
Treatment monitoring clinical application segment is estimated to witness lucrative growth in the projected timeframe. Liquid biopsy efficiently monitors the treatment efficacy than other conventional cancer detection techniques, driving the segmental growth.
Breast cancer segment will hold considerable revenue size of the global liquid biopsy market. Growing adoption of unhealthy lifestyle and eating habits, less child-bearing and hormone replacement therapies are the major risk factors for breast cancer. Also, increasing preference for non-invasive procedures will impel the demand for liquid biopsy over imaging alternatives for breast cancer screening.
Circulating tumor cells (CTCs) will foresee robust revenue growth. High growth is attributed to presence of regulatory approved assays for detecting CTCs. CTC quantification in the blood gives accurate identification of cancer and its progression, thus offering attractive segment growth opportunities over the future years.
Blood sampling liquid biopsy market segment will account for substantial market share in the projected timeframe. Blood sample allows the laboratory technician to identify cancer cells from a tumor or DNA fragments from tumor cells circulating in the blood. Multiple sampling of blood over time can assist doctors to identify the changes the tumor. Aforementioned benefits will help in segmental growth over the forecast timeframe.
Reference laboratories segment is estimated to foresee rapid growth owing to expansion of laboratory tests offered by these facilities. Many firms are collaborating with reference laboratories to facilitate focused testing and reduce operational costs. In addition, growing adoption of liquid biopsy will expand the segmental growth in the forthcoming years.
The U.S. liquid biopsy market is projected to foresee robust growth owing to growing funding for research and development activities in healthcare diagnostics field across the country. Research efforts in the field of oncology for early detection will offer rapid growth opportunities. In addition, rising incidence of various cancer forms such as breast cancer and prostate cancer will augment U.S. liquid biopsy industry growth during the estimation period.
Some of the key industry players in the global liquid biopsy industry include Qiagen, Biocartis, F. Hoffmann-La Roche Ltd., and Myriad Genetics among the other players. Key strategies undertaken by these firms include new test launch and collaborations to expand their market presence and profitability.
Liquid Biopsy Market By Product, 2014-2025 (USD Million)
- Assay Kits
Liquid Biopsy Industry By Clinical Application, 2014-2025 (USD Million)
- Early Cancer Screening
- Treatment Monitoring
Liquid Biopsy Market By Cancer Type, 2014-2025 (USD Million)
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Other Cancers
Liquid Biopsy Industry By Biopsy Biomarker, 2014-2025 (USD Million)
- Circulating Tumor DNA (ctDNA)
- Circulating Tumor Cells (CTC)
- Cell free DNA (cfDNA)
Liquid Biopsy Market By Sample Type, 2014-2025 (USD Million)
- Blood Sampling Liquid Biopsy
- Urine Sampling
- Saliva and Other Tissue Fluids
Liquid Biopsy Industry By End-use, 2014-2025 (USD Million)
- Reference Laboratories
- Physician Laboratories
- Research Laboratories
The above information is provided for the following regions and countries:
- North America
- Asia Pacific
- Latin America
- Middle East and Africa
- South Africa
- Saudi Arabia
- Bio-Rad Laboratories
- F. Hoffmann-La Roche Ltd.
- Genomic Health
- Myriad Genetics
- Thermo Fisher Scientific
What Information does this report contain?
Customize this Report
Our Market Research Reports Include:
- Market snapshot
- Market Segmentation
- Value Chain Analysis
- Growth Dynamics
- Potential Market Opportunities
- Regulatory Overview
- Technology Evolution
- Innovation & Sustainability
Benefits of Association
Data Coverage & Quality
GMI reports provide the most comprehensive coverage of any focus industry, ensuring a holistic and deep understanding of the market, along with actionable and granular data. We also take pride in our commitment to quality and strive to ensure that our clients get their moneys worth.
Client Trust & Security
GMI maintains strict code of conduct as a business and is committed to ensure that the privacy and trust of our clients are always maintained. As an organization, we also strive to be fully compliant with privacy laws, PCI and information security guidelines.
Our customers rely on us to produce accurate, reliable and timely information. Service orientation is a key mission for us as an organization; our process is guided by the desire to ensure that our clients are provided the best possible solutions in optimal timeframe. GMI stands by its commitment to service, providing timely assistance in both pre-sales and post-sales support for our clients.